Delivery Order SPE2DB24D2205-SPE2DB26FDSKC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $4,531.80. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation and is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 22, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This is a firm fixed-price delivery order with a ceiling value of $4,531.80 and an ultimate completion date of May 23, 2025. The contract is non-competitive with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a firm fixed price ceiling value of $9,063.60 and an ultimate completion date of May 5, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Humira (CF) Pen 40 mg/0.4 mL on June 16, 2025, with a ceiling value of $2,392.44. This is a firm fixed-price delivery order with no set-aside designation, meaning the award was competitively granted to the vendor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 17, 2025. As a child contract, this delivery...
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $11,971.22 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB26FDSKCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls with a ceiling value of $15,815.48 under a firm fixed-price contract. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made on a competitive basis with no set-aside designation. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving critical federal medical procurement needs for military and veteran healthcare systems through its comprehensive product portfolio spanning brand-name and generic medications, vaccines, and specialized medical supplies. This specific delivery order for HUMIRA, a biologic immunosuppressant used to treat inflammatory conditions, aligns with the company's extensive track record of fulfilling pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency and other federal healthcare customers. The delivery order is scheduled for ultimate completion by October 16, 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.8k | 10/15/25 |